Close

Press Releases

Biotech Capital on the Rise and Outsourcing to Accelerate in 2025 – but Uneven Growth for CDMOs

European Biotech Recovery Gains Momentum as Chinese Biotech Declines, and IPO Activity Remains Weak New research launched at CPHI Milan – the world’s largest pharma event, held at Fiera Milano (October 08-10, 2024) – forecasts promising growth for biotech and...

CPHI Milan Report: CMOs and hybrid companies will hold 54% of biologics capacity in 2028

CMOs will account for four of the five biggest capacity holders in 2028, with 45% of all CMO capacity in Asia The world’s largest pharma event, CPHI Milan, is set to open at Fiera Milano from October 8- 10, 2024,...

iNova Pharmaceuticals launches iPITCH 2024 – a global crowdsourcing initiative

iNova Pharmaceuticals, in partnership with CoVentured, is thrilled to launch ‘iPitch 2024’, a global crowdsourcing initiative which aims to discover the latest, science-backed innovations in the field of ‘wound care’. iPitch offers product and packaging developers, innovators, research and development...

Recipharm and Exela announce exclusive strategic alliance

Sterile manufacturing capability in the US with over 100 million readily-available units (including vials and Pre-Filled Syringes – PFS) Extensions to include ADCs and auto-injector assembly Site accredited by FDA (CDER and CBER) 1st October 2024 - Recipharm, a leading...

CPHI Milan Survey faster CDMO growth in 2025 predicted and industry not in favour of BIOSECURE Act

CPHI Milan – the world’s largest pharma event, held at Fiera Milano – returns next month at a pivotal moment as contract services growth is predicted to accelerate in 2025. These predictions stem from new research findings from 280...

Roquette Celebrates Expanded Capabilities One Year after Qualicaps Acquisition at CPHI 2024

Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical and nutraceutical excipients, welcomes CPHI Milan attendees to explore the synergistic potential of its expanded excipients portfolio, a year after the acquisition of leading capsule manufacturer,...

AbZelectPRO enables biopharma customers to reach their research cell bank in 10 weeks with 8g/L

Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced that its mammalian cell line development platform, AbZelectPRO™, has significantly reduced its timelines by >30% and improved its overall protein production levels. The platform now offers biopharma customers the ability to bridge...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read